HIV / AIDS in the News

'Paradigm-shifting' study confirms effectiveness of long-acting HIV treatment - University of Cincinnati

 

President Trump: Save Florida’s AIDS Drug Assistance Program! - AIDS Healthcare Foundation

 

New HIV drug may end multi-pill regimen for older people - DW.com

 

CROI 2026: Meaningful Progress, Expanding Choice - avac.org

 

Positive 12-month data shows lotivibart maintains high levels of viral suppression in long-acting HIV treatment regimen - The Pharma Letter

 

Florida Department of Health cuts millions of dollars in funds from HIV and AIDS drug program - CBS News

 

Very Early ART Initiation in Children With HIV Could Lead to ART-Free Remission - MedPage Today

 

Injectable ART Suppressed HIV Long-Term in Teens - MedPage Today

 

Southern Nevada's Black community continues to face higher-than-average HIV rates - KNPR

 

[CROI 2026] Life4me+: Doravirine/islatravir for initial HIV therapy: A two-drug strategy in a three-drug world - European AIDS Treatment Group

 

GSK's ViiV confirms staying power of long-acting HIV treatment Cabenuva in adolescents - Fierce Pharma

 

Valley Healthcare to offer two opportunities for free HIV testing in March - WRBL

 

[CROI 2026] aidsmap: Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens - European AIDS Treatment Group

 

Why is Florida ending longtime HIV drug assistance to more than 10,000? - Naples Daily News

 

Why is Florida ending longtime HIV drug assistance to more than 10,000? - The Palm Beach Post

 

Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens - Aidsmap

 

[CROI 2026] [Press release] ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen - European AIDS Treatment Group

 

[CROI 2026] [Press release] ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing - European AIDS Treatment Group

 

PrEP uptake was already low – and then came the cuts - Aidsmap

 

New data adds to case for bictegravir and lenacapavir in HIV - The Pharma Letter

 

[CROI 2026] [Press release] Merck announces late-breaking data from three Phase 3 trials evaluating doravirine/islatravir, an investigational, once-daily, two-drug regimen for the treatment of adults living with HIV-1 - European AIDS Treatment Group

 

Thousands of Floridians could lose HIV medication - Jacksonville Today

 

From Ending the HIV Epidemic to Uncertain Ground: PrEP4All's Peter Staley - AJMC

 

Counting the costs of global HIV funding disruptions - Aidsmap

 

BIC LEN HIV treatment experienced comorbidites - Infectious Disease Special Edition

 

HIV medications could be cut off as of Sunday for thousands of Floridians - WGCU

 

HIV drug medication bill moving through GA legislature - 11Alive.com

 

[CROI 2026] aidsmap: Dual immune modulators delay, but don’t prevent, HIV rebound after stopping antiretrovirals - European AIDS Treatment Group

 

Military+HIV+enlistment+ban+upheld+by+4th+circuit - North Carolina Lawyers Weekly

 

After 40 years of struggle: Scientists approach the greatest goal in medicine - The Jerusalem Post